Deployable Medical Countermeasures for Warfighter Readiness
Abstract
Maintaining robust protection and treatment against infectious disease threats during stabilization operations (e.g., Humanitarian and Disaster Relief [HADR]) can cause a drug discovery, manufacturing and supply chain burden. A major limitation of our current response to emerging biological and chemical threats is the lack of immediate availability of ideal medical countermeasures (MCMs) for rapid response. The Deployable Medical Countermeasures for Warfighter Readiness program aims to develop an on-demand deployable platform to manufacture nucleic acid drugs at scale, in short timeframes. The platform will be comprised of a fully contained system capable of selectively manufacturing relevant doses of current Good Manufacturing Process (cGMP) grade nucleic acid therapeutics at or near the point of care. This on-demand platform will enable countermeasures capable of combating novel threats, allowing a small force to prevent regional outbreaks from becoming global emergencies.
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2023
- Source ID
- dabd2962608353757ecdf0ed95eb7f0c
Related Documents
- Root: BIOMEDICAL TECHNOLOGY